Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction.
Lowering elevated low-density lipoprotein (LDL) cholesterol is a key management principle in reducing the risk of coronary artery disease (CAD). An aggressive approach to CAD risk reduction requires multiple therapeutic strategies, as no single approach is likely to succeed independently. The use of combination therapy for elevated LDL cholesterol is effective for CAD risk reduction. In fact, the majority of patients with CAD are unlikely to achieve their treatment goals with monotherapy. This article reviews the use of combination therapy for the management of elevated LDL cholesterol, highlighting important therapy considerations.
McKenney
Jim
J
National Clinical Research, Richmond, Virginia 23294, USA. jmckenney@ncrinc.net
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D009525:Niacin / Q000627:therapeutic use; D017410:Practice Guidelines as Topic
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D009525:Niacin